



PROMs and PREMs in ENROL

- Mariangela Pellegrini, Educational and Patients Program Manager, ERN-EuroBloodNet
- Jacqueline Dubow, ERN-EuroBloodNet ePAGs, MDS Alliance, CCM

From ERICA WP3 team: Mar Mañú Pereira, Ana Rath, Céline Desvignes-Gleizes, Mariangela Pellegrini, Gavin McDonough, Caterina Lucano

ENROL CONSORTIUM





Coordinator

Maria del Mar Mañú Pereira Victoria Gutiérrez Valle

Vall d'Hebron University Hospital Vall d'Hebrón Research Institute Barcelona, Spain



Béatrice Gulbis

Erasme University Hospital LHUB-ULB Brussels, Belgium







Pierre Fenaux Mariangela Pellegrini

Assistance Publique - Hopitaux de Paris Paris, France



Marina Kleanthous Petros Kountouris

The Cyprus Foundation for muscular dystrophy research Nicosia, Cyprus

ENROL is endorsed by the European Hematology Association





Keys concepts from past webinars

- A registry is a platform that collects patients data like diseases, country, age, treatments
- ENROL maps common data across existing registries in Europe facilitating to monitor a disease across Europe and helping research and policy' development for rare haematological diseases.
- ENROL gathered data that in Europe would have been fragmented in one central platform. Enrol
 makes them understandable, accessible and reusable by researcher and policy makers and
 guarantying patients' privacy!
- Registries facilitate not only research but also patient-centric research



Learning objectives of the webinar

Main objective: The impact of PROMs and PREMs and the benefits of associating them to registries

Addressed questions


- What are PROMs & PREMs?
- What are the benefits of using them for patients and for scientific communities?
- What do I need to know about PROMs & PREMs before including them in a registry?
- Where can I find adequate PROMs & PREMs and who can I address to have more info on PROMs & PREMs?
- How to use PROMs & PREMs for Advocacy?



What are PROMs and PREMs?



Let's imagine a Clinical Trial on a drug for increasing the hemoglobin









- Fatigue.
- Weakness.
- Pale skin and gums.
- Shortness of breath.
- A fast or irregular heartbeat.



Hemoglobin 7



With this new drug....



- Fatigue.
- Weakness.



Hemoglobin 14







- Fatigue.
- Weakness.

I feel still almost the same, I don't know if the drug works!




Hemoglobin 14: the drug works!!!

Another example



Why Patient Perception Matters

Question:BT done in a room with other patients













So: how to integrate the perception of the patient into the clinical outcomes of the trial?



Patient-Reported Outcomes Measures (PROMs): Definition


"A measurement based on a report that **comes directly Trom the patient** (i.e., study subject) about the status of a patient's health condition **without amendment or interpretation** of the patient's response by a clinician or anyone else. A
PRO can be measured by **self-report** or **by interview** provided that the interviewer records only the patient's response"

FDA, 2009, "Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims"



PROMs belong to Clinical Outcome Assessment Measures

Clinical Outcome Assessment (COA)



To type of COA is determined by the perspective/point of view that is rated

PROMs structure



DERMATOLOGY LIFE QUALITY INDEX

The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick ✓ one box for each question.

- 1. Over the last week, how itchy, sore, painful or stinging has your skin been?
- Over the last week, how embarrassed or self conscious have you been because of your skin?

Very much		3			
A lot A little Not at all	-	2 1 0	_		
Very much A lot A little Not at all		3 2 1 0	\		\

Instructions

Item (= question) : it contains the
measured concept and the recall period

Response options

Number of response options

Item Score

PROMs structure

The a	The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick ✓ one box for each question.					
1.	Over the last week, how itchy , sore , painful or stinging has your skin been?	Very much A lot A little Not at all				
2.	Over the last week, how emberrassed or self.conscious have you been because of your skin?	Very much A lot A little Not at all				
3.	Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?	Very much A lot A little Not at all	0000	Not relevant □		
4.	Over the last week, how much has your skin influenced the clothes	Very much A lot	0 0 0	Not relevant □		
	you wear?	A little Not at all		Not relevant □		
5.	Over the last week, how much has your skin affected any social or leisure activities?	Very much A lot A little Not at all		Not relevant □		
6.	Over the last week, how much has your skin made it difficult for you to do any sport ?	Very much A lot A little Not at all		Not relevant □		
7.	Over the last week, has your skin prevented you from working or studying?	Yes No		Not relevant □		
	If "No", over the last week how much has your skin been a problem at work or studying?	A lot A little Not at all				
8.	Over the last week, how much has your skin created problems with your partner or any of your close friends	Very much A lot A little				
	or relatives?	Not at all	-	Not relevant □		
9.	Over the last week, how much has your skin caused any sexual difficulties?	Very much A lot A little Not at all		Not relevant □		
10.	Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?	Very much A lot A little Not at all		Not relevant □		



Domain(s) covered by the questionnaire

- Symptoms and feelings (2 items)
- Daily activities (2 items)
- Leisure (2 items)
- Work and school (1 item)
- Personal relationships (2 items)
- Treatment (1 item)



PROM development

(according to FDA 2009 PRO guidance*)

1. Item generation













Literature Review

Patients interviews

Clinicians interviews

List of preliminary items (based on a conceptual model)

2. Preliminary questionnaire test



Patient's understanding assessment



Statistical analysis (incl. domain scoring definition)



Modifications
(# of items, response options, etc.)



Final scored questionnaire

3. Measurement properties





Statistical validation showing PROM **reliability**, **validity** and **responsiveness/ability to detect change**



1 – 3 years



Patient-Reported Experience Measures (PREMs): Definition

Patient-reported experience measures (PREMs) are questionnaires measuring the patients' perceptions of their experience, the quality of care whilst receiving care. In contrast to PROMs, PREMs do not look at the outcomes of care but the impact of the process of the care on the patient's experience e.g. communication, health care staff relationship and timeliness of assistance

Charlotte Kingsley, MBBS BSc FRCA, Sanjiv Patel, MBBS BMedSci FRCA, Patient-reported outcome measures and patient-reported experience measures, BJA Education, Volume 17, Issue 4, April 2017, Pages 137–144"

PREMs structure





ENERCA Patient Questionnaire

"Patients' Needs and Expectations of Expert Centres in Haemoglobin Disorders"

This questionnaire should be answered by patients over 15 years old, or parents of patients under the age of 15. Please read the accompanying letter before answering. All information will be treated as confidential.

<u>Please note</u>: Section 3 (including 3a and 3b) is obligatory. Sections 1, 2 and 4 are optional, but it will be helpful it you complete them also.

Section 1 – About the patient (optional section)						
04	Overting a second to the					
Q1.	Questionnaire completed by:					
	Patient					
	Parent					
	Other (e.g., relative, helper, Please specify:					
Q2.	Patient's age:					
Q3.	Patient's gender					
Q4.	Patient's marital status Married Single Cohabiting					
	☐ Divorced ☐ Children (number:)					



Instructions

PREMs structure



Section 3	- The medical services you (the patient) are currently using		Q20.	Is access to the treatment centre (in	ess to the treatment centre (in terms of distance, cost etc.):			
Q15.	Where do you receive medical treatment for your condition? (tick all that apply)			= '	?			
	Specialised haemoglobinopathy centre General haematology department at a hospital General paediatric department of a hospital Private clinic/centre (non-specialist) Other (describe)	Score	Q21.	Who pays for your treatment? (Tick a Myself/my family Health insurance (private): Mine Health insurance (state) State-provided free healthcare Other model of payment	_			
Q16.	How long do you usually wait for a transfusion to be set up? Under 30 min	Question		Please describe:				
Q17.	Where are you transfused? Haematology day unit Adult Haematology ward Children's ward Accident & Emergency		Q22.		dition to your main treating of visits:			
Q18.	When are you usually transfused? Morning Afternoon Evening Overnight Weekend	Respons	se					
Q19.	The treatment centre where you go for treatment is located:	options		_	of visits: of visits:			
	Local/near where I live Another region / city		Q23.	Where do you see the specialist(s)?	(Tick all that apply)			
	Another country If so, why do you go to another country treatment?			Same hospital				



What do I need to know about PROMs & PREMs before associating them in a registry?



"Measuring What?" What do you need to hear from patients?





"Measuring What?": What do you need to hear from patients?



Describe disease burden

on patients quality of life (QOL) with PROMs&PREMs Eg Generic and Disease-Specific QoL scales



Assess quality of care

with PREMs

Eg Generic and ERN-Specific PREMs scales



Evaluate treatment impact

on functioning with validated function-specific scales (ClinROs, PerfOs, PROMs)

Eg Mobility-specific scale



Capture patient perception of change in symptoms: with PROMs symptom-specific scales and ad-hoc diaries Eg Pruritus VAS & 5D-Itch





"What for?"

Clarification of PROMS/PREMs-related objective is a prerequisite!





PROMs/PREMs, What for?

- Patient Management
- Guidance / Education:

Dissemination of current knowledge to physicians

Support medical decision-making

Improvement of diagnosis and treatment decisions

Enhance communication

Support patient-and-doctor-interaction on description of symptoms, complaints about functional impact and expected treatment benefits

Health Care Management:

Evaluation of Efficiency of Care in Real-World Practice

Clinical Research:

Evaluation of intervention effects (care, drug, device, surgery, physiotherapy, etc.)



The context of use determines the PROMs/PREMs selection






The context of use determines your PROMs/PREMs selection

Example: Measure of depression

- Screening:
 - Hospital Anxiety and Depression Scale (HADS 14 items): Quick completion time and immediate scoring
- Assessment of programs Measure of depression impact on HRQoL:
 - Quality of Life in Depression Scale (QLDS 34 items)
 - SF-36 (36 items)
 - Work Productivity & Activity Impairment Questionnaire (WPAI:D 6 items)
- Assessment of mid-term outcomes of care on all patients from hospital:
 - Motivation and Energy Inventory (MEI-SF 18 items)
- Assessment of intervention:
 - Montgomery-Asberg Depression Rating Scale (MADRS 10 items/signs and symptoms)

In a nutshell







Criteria to consider to favor acceptance by patients and adoption by clinicians

- Feasible: PROM/PREM should be easy-to-use (e.g. NRS vs VAS)
- Actionable: PROM/PREM score should easily lead to decision-making and action
- In-Context: PROM/PREM should be incorporated into the provider's routine process of care
- **Useful:** PROM/PREM collection and processing should contribute to **better** healthcare



Beyond PROMs/PREMs validity, <u>acceptance by patients</u> and adoption by clinicians is critical









IMPORTANCE OF EARLY PATIENTS ENGAGEMENTS OF ALL OF THOSE ACTIVITIES





Why to have data issued from PROMs is important for advocacy?




PROMS/PREMs provide evidences and not just expressed needs or burdens





Patient community expressing needs and burdens based on their experiences orally



Patient community expressing needs and burdens based on their experiences gathered in a questionnaires







"Patients' Needs and Expectations of Expert Centres in Haemoglobin Disorders"

This questionnaire should be answered by patients over 15 years old, or parents of patients under the age of 15. Please read the accompanying letter before answering. All information will be treated as confidential.


<u>Please note</u>: Section 3 (including 3a and 3b) is obligatory. Sections 1, 2 and 4 are optional, but it will be helpful it you complete them also.

Section 1 – About the patient (optional section)					
Q1.	Questionnaire completed by	r:			
	Patient				
	Parent				
	Other (e.g. relative, helper, patient association representa	☐ Please specify:tive)			



Some examples issued from this questionnaire








« I spend a lot of time in day unit for receiving transfusion. I loose time from school or work » **Need** "The provision of transfusions in a timely manner and at convenient for the patient hours".

The majority of responders 256/401 (63.84%) are transfused in morning

Q18. Time of transfusion	Number of patients	Percentage
Morning	256	63.84%
Afternoom	117	29.18%
Evening	9	2.24%
Overnight	10	2.49%
Weekemd	8	1.99%
Other (hospitalised for 3-5 days)	1	0.25%








« I spend a lot of time in day unit for receiving transfusion. I loose time from school or work »

Need "The provision of transfusions in a timely manner and at convenient for the patient hours".

Of the patients transfused in the morning 30.7% are working full time, 13% are working part time and 21.6% are not working







Need "The provision of transfusions in a timely manner and at convenient for the patient hours".

Need: "The right to work"

The majority of responders 256/401 (63.84%) are transfused in morning, 13% are working part time and 21.6% are not working

Quantitative evidence (KPIs) -> basis for shaping Health Planning or centre Health Delivery








My center doesn't garantee me a good aderhence to treatments. I experience a lot of pain

of 126 patients who claimed regularity in taking medication 91 (72.22%) were being treated in specialised centres, while 35 (27.77%) in other departments.

In this cohort of patients 31.45% were receiving Desferrioxamine monotherapy daily while another 19.62% were on a combination of the subcutaneous drug and an oral chelator (Deferiprone)

so more than half still had to adhere to difficult and painful treatment.









Need "Adherence to lifelong treatment requires support from the healthcare providers"

35 (27.77%) are not treated in expert centers.


In this cohort of patients 31.45% were receiving Desferrioxamine monotherapy daily while another 19.62% were on a combination of the subcutaneous drug and an oral chelator (Deferiprone)

Quantitative evidence (KPIs) -> basis for shaping Health Planning or centre Health delivery



In the registries
PROMs and PREMs are
associated for
providing source of
data!

Daily activities	90%
Symptoms and feeling	82%
Personal relationships	87%





Systematic gathering of evidences via registries associating PROMs and PREMs

ACHIEVEMENTS

Using them for Advocacy

Involvement in the process of determinates baskets of benefits within a social health security rights



Hospital provided with transfusion canters opened in the late afternoon




Formal recognition of disabilities, impairments and handicaps

Having right to more days off from work



PROMs and RDs challenges






Where as patient representative I can find adequate PROMs & PREMs?





PROMs and RDs challenges





WP3team Patient-Centric Reaserch





Ana Rath
Director
Orphanet
ERICA WP3 Co-lead



Mariangela Pellegrini
Educational & Patients Program manager EuroBloodNet
Assistance Publique - Hôpitaux de Paris (APHP)



Gavin McDonoughPosition
Orphanet



Céline Desvignes-GleizesKnowledge management and partnerships
Mapi Research Trust / ICON



Mar Mañu Pereira
Principal Investigator
Vall d'Hebron Institute of Research
(VHIR)
ERICA WP3 Co-lead



PROMs selection strategy results

■ PROQOLID™ search

- 1. PROMs developed in Rare diseases (259 PROMs)
- 2. Generic Quality of life PROMs (160 PROMs)
- 3. PROMs measuring functional impacts (ex: Understanding, *etc.*) (151 PROMs)
- ERN members survey (211 PROMs)
- → Total PROMs identified: 781 PROMs
- → ObsRO will be included in the repository in upcoming month
 - → 132 ObSRO including 15 developed in RD

RD PROMs/PREMs repository



ERICA Home A	oout ▼ Work Packages ▼	ERNs News				
♠ • Work Packages • WP3 Patient-Ce	ntred Research • PROMs Repo	sitory				
PROMs Repos	itory					
The ERICA Patient Reported Outcorrare diseases and constitutes a mil possible through the joint collabor methodology for the constitution a	me Measures (PROMs) Repo estone in the Europe-wide s ation between Orphanet, M	tandardization of Patient api Research Trust/ICON	-Centered Outcome Measures (PCG and ERN EuroBloodNet (VHIR, APH	DMs) and PROMs for rar P), and the active contril	e diseases. It has b	een made
The central repository is a dynamic PROQOLID™.	and evolutive service and s	hould be regarded as a co	entralized and standardized access	gate to more in depth i	nformation contain	ned in
Filters list of PCOMs/F	PROMs					
PCOM/PROM Name 1)			PCOM/PROM Type ²⁾			
Target Age ⁴⁾			Domains ⁵⁾			
Disease (OrphaName) ⁶⁾			OrphaCode ⁷⁾			
Group of Diseases ⁸⁾			ERNs 9)			
1 Legend						
Search Reset				Column	n Visibility ▼	Column Reset
					Showing	811 PCOMs/PROM
PCOM/PROM Name Type	PROQOLID™ Age	Domains	Disease (OrphaName) OrphaC	ode Group of Diseases	ERNs	PROQOLID™ ↓
Adult Sickle Cell Quality of Life PRO Measurement Information System® (ASCQ-Me®)	✓ Full Adult	- Emotional impact (20 8ems) - Social functioning (17 8ems) - Pain (13 8ems) - Stiffness (15 8ems) - Sleep functioning (12 8ems)	Sickle cell anemia ORPHA:	232 Rare anemia	ERN EuroBloodNet	% <u>Link</u>
EORTC - Chronic Myeloid PRO Leukaemia (EORTC QLQ-CML24)	✓ Basic Adult	Symptom Burden Impact on Daily Life Impact on Worry/Mood Body Image Problems Satisfaction with Care and	Non-Hodgkin ORPHA: lymphoma	547 Tumor of hematopoietic and lymphoid tissues	ERN EuroBloodNet ERN PaedCan ERN EURACAN	% <u>Link</u>

ERICA PROMs/PREMs repository

https://erica-rd.eu/work-packages/patient-centred-research/promsrepository/



e.g. searching for transfusion related PROMs/PREMs



Search Reset							Colu	mn Visibility▼	Column Rese
transfusion ×								Showing 2 PCOMs/	PROMs (of 811 to
PCOM/PROM Name	Type	PROQOLID™	Age	Domains	Disease (OrphaName)	OrphaCode	Group of Diseases	ERNs	PROQOLID™ Link
Nontransfusion-dependent thalassemia - Patient-reported outcome (NTDT-PRO)	PRO	No	Adult	- Tiredness - Weakness - Shortness of Breath, with or without Physical Activity	Beta-thalassemia	ORPHA:848	Rare anemia	ERN EuroBloodNet	
Specific Thalassemia Quality of Life Instrument (STQOLI)	PRO	No	Adult	- Disease and symptoms (12 items) - Chelation therapy (13 items: (5 items per os chelation therapy users, 5 items for subcutaneous chelation therapy users, and 3 common items)) - Psychosocial impact (10 items) - Transfusion impact (5 items)	Beta-thalassemia	ORPHA:848	Rare anemia	ERN EuroBloodNet	

ERICA PROMs/PREMs repository

https://erica-rd.eu/work-packages/patient-centred-research/proms-repository/



For complete information on PROMs/PREMs





PROMs /PREMs Database

https://eprovide.mapi-trust.org/advanced-search?database=progolid

- Free of access for ERICA members upon request to Mari Murel (m.murel@lumc.nl)
- Database content:
 - Author information
 - Conditions of use
 - Translations
 - Population of development
 - PROMs/PREMs Review copy
 - Information on development and validation of PROMs/PREMs



Systematic gathering of evidences via registries associating PROMs and PREMs

ACHIEVEMENTS

Using them for Research



Let's take a concrete example... of connection among PROMs, registry, research & increasing patients quality of life...



for rare or low prevalence complex diseases

Network

Hematological Diseases (ERN EuroBloodNet)

EXAMPLE FROM THE ERN-EUROBLOODNET

How could Researchers benefit from the data collected by the ERNs and the ERN registries

SCD QoL is similar to
Cancer: on treatment
Vaso-occlusive Pain
crises are the Primary
reason in emergency departments.

SCD QoL & Pain Crisis

many vaso-occlusive pain crises are managed at home with oral medication that includes

OPIOIDS and supportive care

Differences in output pain management and opioids prescription

How does a new drug /
genetic modifier affect on
vaso-occlusive pain crisis?
What are the eligibility
Criteria for prescribing the drug?

We need PROMs in ERNs Registries




Figure 7 | **Health-related quality of life.** Physical functioning scores measured using the 36-Item Short Form Health Survey (SF-36) and the Pediatric Quality of Life Inventory (PedsQL) generic core scales in healthy individuals and individuals with chronic disease^{237,277}. Scores range from 100, representing the best health-related quality of life (HRQQL), to 0. Specific areas represented in physical functioning scores include the ability to perform all types of physical activities, such as running, walking for a short distance, lifting heavy objects and bathing without help.











Network
HematologicalDiseases (ERN EuroBloodNet)



Co-funded by the European Union

"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them."